| First Author | Akporiaye ET | Year | 2007 |
| Journal | Vaccine | Volume | 25 |
| Issue | 39-40 | Pages | 6965-74 |
| PubMed ID | 17707958 | Mgi Jnum | J:128727 |
| Mgi Id | MGI:3767913 | Doi | 10.1016/j.vaccine.2007.06.063 |
| Citation | Akporiaye ET, et al. (2007) Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine 25(39-40):6965-74 |
| abstractText | A bigenic MUC1.Tg/MIN mouse model was developed by crossing Apc/(MIN/+) (MIN) mice with human MUC1 transgenic mice to evaluate MUC1 antigen-specific immunotherapy of intestinal adenomas. The MUC1.Tg/MIN mice developed adenomas at a rate comparable to that of MIN mice and had similar levels of serum MUC1 antigen. A MUC1-based vaccine consisting of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, unmethylated CpG oligodeoxynucleotide and GM-CSF caused flattening of adenomas and significantly reduced the number of large adenomas. Immunization was successful in generating a MUC1-directed immune response evidenced by increased MUC1 peptide-specific anti-tumor cytotoxicity and IFN-gamma secretion by lymphocytes. |
